Survey on VPRIV home infusion education use and understanding
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This trial is a survey study asking Gaucher disease patients, their caregivers, and home infusion nurses about how they use and understand educational materials for VPRIV (velaglucerase alfa) given at home. Your feedback may help improve patient and caregiver education and nurse materials for home infusions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have Gaucher disease and receive VPRIV (velaglucerase alfa) by home infusion
- You (or your caregiver) will be willing to complete a survey
- If you are a caregiver, you support someone who receives VPRIV at home
- If you are a nurse, you administer VPRIV to Gaucher disease patients in their homes
- You do not have a conflict of interest related to the survey (for example, working for regulators or the pharmaceutical industry)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how Gaucher disease affects patients’ daily life and health outcomes through a survey. Your answers could help improve future care and treatments by showing what outcomes matter most.
This study is designed to learn what happens over time in people who have Gaucher disease. It may help researchers understand the long-term effects of the condition and improve future care.
This study looks at how standard treatments for Gaucher disease affect lung problems, bone damage, and parkinson-like symptoms. It aims to find better ways to treat these complications and improve quality of life.
This study looks for tiny particles in blood (called extracellular vesicles) that may help identify Gaucher disease and could guide future treatments. It also studies people who have Gaucher gene carrier status but do not have the disease, using careful genetic testing.
This study creates a large, long-term record of people with Gaucher disease and details about pregnancy outcomes. It helps researchers better understand Gaucher over a person’s life and during pregnancy.
This study tests an oral medication (eliglustat) for children with Gaucher disease types 1 and 3, replacing enzyme infusions. It may help maintain disease control with a simpler treatment.
Hear when a new Gaucher Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.